Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial

OBJECTIVE: To assess the efficacy and safety of the glucagon-like peptide 1 receptor agonist (GLP-1 RA) efpeglenatide versus placebo in patients with type 2 diabetes inadequately controlled with diet and exercise alone. RESEARCH DESIGN AND METHODS: AMPLITUDE-M was a phase 3, double-blind, placebo-co...

Descripción completa

Detalles Bibliográficos
Autores principales: Frias, Juan Pablo, Choi, JaeDuk, Rosenstock, Julio, Popescu, Luiza, Niemoeller, Elisabeth, Muehlen-Bartmer, Isabel, Baek, Seungjae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2022
Materias:
Emerging Therapies: Drugs and Regimens
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9274225/
https://www.ncbi.nlm.nih.gov/pubmed/35671039
http://dx.doi.org/10.2337/dc21-2656

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9274225/
https://www.ncbi.nlm.nih.gov/pubmed/35671039
http://dx.doi.org/10.2337/dc21-2656

Ejemplares similares